​Mucuna pruriens (Velvet Bean)

CONSULTATION WITH A SPECIALIST

Product code:
67 396.5 ₽
We recommend installing the IMO messenger for quick contact.
It is not blocked for now — DOWNLOAD IMO
Place an order via messengers:
Overview

Mucuna pruriens (Velvet Bean)

Product Name: Мукуна жгучая, Mucuna pruriens, Juckbohne, frijol terciopelo, pois mascate, لوبيا مخملية, ถั่วกำมะหยี่

Synonyms: бархатная фасоль, мукуна, бархатный боб, mucuna bean, velvet bean, cowitch, kapikacchu, Juckbohne, Samtbohne, frijol terciopelo, frijol terciopelo africano, pois mascate, fève velue, لوبيا مخملية, كاويتش, ถั่วกำมะหยี่, หมามุ่ย

Main Indications for Use of Mucuna pruriens: Parkinson's disease, dopamine deficiency syndrome, depression, asthenic syndrome, chronic fatigue syndrome, male infertility, oligospermia, erectile dysfunction, hypogonadism, Alzheimer's disease, anxiety disorder, neurovegetative dysfunction, hypodopaminergic state in ADHD.

Use of Mucuna pruriens in Mixtures and Complexes: Multiple sclerosis, sluggish schizophrenia, Tourette's syndrome, Huntington's disease, vascular dementia, myasthenia, metabolic syndrome, hypothyroidism, post-COVID syndrome, post-traumatic stress disorder.

Pharmacological Properties of Mucuna pruriens: nootropic, neuroprotective, antidepressant, adaptogenic, anxiolytic, antioxidant, spermatogenetic, aphrodisiac, dopaminergic, neuromodulatory, gonadotropic, antiparkinsonian, antipsychotic, immunomodulatory, hepatoprotective, cardiotonic.


Dosage of Pharmaceutical Forms — Mucuna pruriens

Powder — Mucuna pruriens

Indications (Powder): Parkinson's disease, depression, asthenic syndrome, anxiety disorder, chronic fatigue syndrome, oligospermia, erectile dysfunction, hypogonadism, Alzheimer's disease, hypodopaminergic state, male infertility.

Standard Dosage (Powder): 3 g of powder twice daily, on an empty stomach or 30 minutes before meals, washed down with warm water. Course — 30 days.

Enhanced Dosage (Powder): 5 g of powder 2–3 times a day for pronounced manifestations of Parkinson's disease, hypogonadism, severe forms of asthenia, or a significant decrease in libido. Course — up to 45 days under specialist supervision.

Maximum Dosage (Powder): No more than 20 g per day. Recommended only within clinical observation for persistent parkinsonian disorders or severe dopamine deficiency.

Preventive Dosage (Powder): 1.5–2 g of powder per day, in the morning. Recommended for chronic fatigue syndrome, age-related decrease in libido, stress overload, and neurovegetative imbalances. Intake in courses of 20 days with 10-day breaks.

Pediatric Dosage (Powder): For children over 12 years of age and with a body weight from 40 kg — no more than 1 g once daily. Not used in younger children. The child's gender is not a factor.

Contraindications (Powder): Hypertension, hyperthyroidism, psychoses, use of MAO inhibitors, schizophrenia, individual intolerance. Data on safety during pregnancy, lactation, and in children under 12 years of age have not been scientifically registered.

Side Effects (Powder): In case of overdose, possible: insomnia, tachycardia, headache, irritability, nausea, dizziness. Side effects have been registered with the use of doses above 15 g/day.

Adjustment for Patient Body Weight (Powder): For patients with body weight below 60 kg — reduce the dose by 25%. For body weight above 90 kg — a dose increase of 15–20% is permissible in the absence of side effects.

Preparation Method (Powder): To prepare 100 g of powder, ripe, dried Mucuna pruriens seeds are used.

  • Select 150 g of seeds without external damage.
  • Roast the seeds on a dry ceramic surface at a temperature of 90–100 °C for 15 minutes to neutralize the skin irritant.
  • Cool and grind in a mill to a powder-like state.
  • Sift through a fine sieve to remove coarse particles.

The yield of the finished powder is about 100 g. No chemical modification or additives are used.

Storage Conditions and Shelf Life (Powder): Store in a tightly closed container made of glass or dark biodegradable plastic. Temperature range — from 5 to 25 °C. Avoid exposure to direct sunlight, moisture, and electromagnetic fields. After opening — use within 60 days. Total shelf life — up to 12 months in airtight packaging.


Dry Extract — Mucuna pruriens

Indications (Dry Extract): Parkinson's disease, depression, anxiety disorder, neurodegenerative diseases, chronic fatigue syndrome, erectile dysfunction, oligospermia, hypogonadism, Alzheimer's disease.

Standard Dosage (Dry Extract): 250–500 mg of standardized dry extract (with an L-Dopa content of 15–20%) twice daily, 30 minutes before meals. Course — 30 days.

Enhanced Dosage (Dry Extract): Up to 1000 mg of dry extract 2–3 times a day for Parkinson's disease, severe forms of dopamine deficiency, pronounced sexual dysfunction, and neurodegenerative disorders. Course — up to 45 days under specialist supervision.

Maximum Dosage (Dry Extract): No more than 3000 mg per day. Permissible short-term (up to 7 days) for resistant symptoms of Parkinson's disease and pronounced asthenia. Only under medical supervision.

Preventive Dosage (Dry Extract): 250 mg in the morning hours. Used for chronic stress, decreased sexual function, and age-related cognitive changes. Courses — 20 days of intake / 10 days break.

Pediatric Dosage (Dry Extract): From 12 years of age, body weight from 40 kg — 125–250 mg once daily. Under 12 years of age, not recommended due to the absence of confirmed safety data. Gender does not matter.

Contraindications (Dry Extract): Psychoses, schizophrenia, hyperthyroidism, severe forms of arterial hypertension, individual intolerance. Not recommended with MAO inhibitors. Data on use during pregnancy, lactation, and in children under 12 years of age have not been registered in the scientific literature.

Side Effects (Dry Extract): When doses are exceeded, insomnia, irritability, tachycardia, headaches, and dyspepsia are possible. At doses above 2 g/day — cases of orthostatic hypotension and nausea are more frequent.

Adjustment for Patient Body Weight (Dry Extract): Up to 60 kg — reduce the dose by 25%. For body weight over 90 kg, a correction upward by 15–20% is possible.

Preparation Method (Dry Extract): To obtain 100 g of dry extract:

  • Grind 500 g of pre-roasted seeds.
  • Pour with 2 liters of 70% water-alcohol solution.
  • Infuse for 72 hours at a temperature of 25–30 °C.
  • Filter and evaporate the extract at 45 °C in a rotary evaporator to a syrup-like mass.
  • Dry in a vacuum dryer at 40 °C to a dry residue.
  • Grind and sift to a powder. Yield — about 100 g of extract with an L-Dopa content of 15–20%.

Storage Conditions and Shelf Life (Dry Extract): Store in a tightly sealed container in a dry, light-protected place, at a temperature of 5 to 25 °C. Avoid contact with moisture and sources of electromagnetic fields. Shelf life — 24 months. After opening, use within 60 days.


Alcohol-Based Tincture — Mucuna pruriens

Indications (Tincture): Parkinson's disease, depression, anxiety disorders, neurovegetative dysfunction, decreased libido, asthenic syndrome, oligospermia, age-related cognitive dysfunction.

Standard Dosage (Tincture): 20 drops (approximately 1 ml) of tincture in 70% alcohol twice daily, 30 minutes before meals. Dilute in 50 ml of warm water. Course — 21–30 days.

Enhanced Dosage (Tincture): 30–35 drops 3 times a day for pronounced dopamine deficiency, Parkinson's disease, severe asthenia, or sexual dysfunction. Course — 30 days under medical supervision.

Maximum Dosage (Tincture): Up to 45 drops 3 times a day (≈6 ml/day) only under specialist supervision for persistent hypodopaminergia. Duration — no more than 7 days.

Preventive Dosage (Tincture): 10–15 drops once daily in the morning. Used for chronic fatigue syndrome, age-related decrease in energy, emotional burnout, and premenopausal neurovegetative imbalance. Courses — 20 days with a 10-day break.

Pediatric Dosage (Tincture): Not used under 12 years of age. From 12 years of age and body weight from 40 kg — 5 drops once daily. Dilute in 30 ml of water. Use is permissible only according to indications and under supervision.

Contraindications (Tincture): Psychoses, hypertension, schizophrenia, thyrotoxicosis, epilepsy, alcohol dependence, use of MAO inhibitors, individual intolerance. No reliable data on use during pregnancy, lactation, and in children under 12 years of age have been registered.

Side Effects (Tincture): When doses are exceeded, insomnia, palpitations, increased anxiety, headache, and dizziness are possible. Dyspeptic reactions have been noted.

Adjustment for Patient Body Weight (Tincture): For patients with body weight up to 60 kg — reduce the dosage by 20%. Over 90 kg — a 15% increase is permissible.

Preparation Method (Tincture): To prepare 100 ml of tincture:

  • Grind 20 g of dry Mucuna seeds.
  • Place in a dark glass container and pour 100 ml of 70% ethyl alcohol.
  • Infuse for 14 days in a light-protected place at a temperature of 18–25 °C, shaking daily.
  • Upon completion, strain the tincture through gauze and store in a tightly closed container.

Storage Conditions and Shelf Life (Tincture): Store in a dark glass container at a temperature of 10–25 °C, away from sources of light, heat, and EMI. Shelf life — up to 3 years. After opening, use within 3 months.


Oil Infusion — Mucuna pruriens

Indications (Oil Infusion): Erectile dysfunction, oligospermia, male infertility, decreased libido, muscle hypotonia, chronic fatigue, neuralgias, joint pain.

Standard Dosage (Oil Infusion): 5 ml of infusion (externally) twice daily, applied to the lower abdomen, lumbar region, or inner thigh for sexual dysfunction, or to the problem area for muscle or joint tension. Course — 14–21 days.

Enhanced Dosage (Oil Infusion): 7–10 ml of infusion twice daily, rubbing intensively into the sacral and inguinal area for pronounced hypogonadal symptoms, or into the area of pain syndrome for chronic neuralgias and myalgias. Course — up to 30 days.

Maximum Dosage (Oil Infusion): Up to 15 ml per day for severe sexual dysfunction or chronic musculoskeletal pain syndrome. Used no more than 10 consecutive days, then — a 7-day break.

Preventive Dosage (Oil Infusion): 2–3 ml of infusion once daily in the evening, applied to the lumbar or inguinal region. Prevention of age-related testosterone decline, asthenization, and emotional burnout. Courses — 15 days of intake with an interval of 15–20 days.

Pediatric Dosage (Oil Infusion): Not used in children. The safety of external use of the infusion in childhood has not been scientifically confirmed.

Contraindications (Oil Infusion): Skin damage, dermatitis, individual intolerance, hyperandrogenism, acne. Data on contraindications during pregnancy, lactation, and in childhood have not been scientifically registered.

Side Effects (Oil Infusion): Local reactions: skin redness, itching, hyperemia, in rare cases — eruptions. When used in large doses, insomnia and nervousness are possible (due to systemic absorption).

Adjustment for Patient Body Weight (Oil Infusion): For patients with body weight up to 60 kg — use no more than 5 ml per day. For body weight over 90 kg, an increase in dosage to 12–15 ml is permissible.

Preparation Method (Oil Infusion): To obtain 100 ml of infusion:

  • Grind 20 g of dry Mucuna seeds (after heat treatment at 100 °C).
  • Mix with 100 ml of cold organic sesame oil (or macadamia oil).
  • Simmer in a water bath at a temperature of 40–45 °C for 6 hours, stirring periodically.
  • Cool, filter through cloth or gauze, and pour into a dark bottle.
  • Yield — about 95 ml of finished infusion.

Storage Conditions and Shelf Life (Oil Infusion): Store in dark glass at a temperature of 10–20 °C, away from sources of light, moisture, and heat. Shield from electromagnetic radiation. Shelf life — up to 6 months. After opening, use within 45 days.


Ointment — Mucuna pruriens

Indications (Ointment): Muscle spasms, localized neuralgias, pain syndrome in radiculitis, asthenization, local manifestations of erectile dysfunction (external use), decreased sensitivity, chronic myositis.

Standard Dosage (Ointment): Apply 1–2 g of ointment to the affected area twice daily, evenly distributing over the skin. Rub in with light movements until absorbed. Course — 10–14 days.

Enhanced Dosage (Ointment): 3–4 g of ointment 2–3 times a day, especially for pronounced pain syndrome, spasms, or myalgia. It is recommended to rub the ointment with a mild warm compress. Duration — no more than 21 days.

Maximum Dosage (Ointment): Up to 6 g of ointment per day. Permissible short-term (up to 7 consecutive days) for acute pain syndrome. After — a mandatory 5-day break.

Preventive Dosage (Ointment): 1 g of ointment on the sacral, neck, or shoulder girdle area once daily for 7–10 days. Used for the prevention of seasonal exacerbations of neuralgia, chronic fatigue, and office tension syndrome. Repeat course — after 2 weeks.

Pediatric Dosage (Ointment): Not used in children under 14 years of age. From 14 years of age, local use of no more than 0.5–1 g once daily is possible with a body weight from 45 kg.

Contraindications (Ointment): Open wounds, skin diseases in the exacerbation stage, individual intolerance. There are no data on use in pregnant and breastfeeding women. In children under 14 years of age, use is not recommended.

Side Effects (Ointment): Local skin irritation, itching, hyperemia. With repeated use — dry skin is possible, in rare cases — contact dermatitis.

Adjustment for Patient Body Weight (Ointment): For patients up to 60 kg — no more than 1.5 g of ointment per day. Over 90 kg — a dosage increase to 4 g per day is possible.

Preparation Method (Ointment): To prepare 100 g of ointment:

  • 10 g of Mucuna pruriens seed powder, pre-roasted and crushed.
  • 90 g of base: melted ghee (50 g) and black cumin oil (40 g).
  • Melt the base in a water bath at a temperature of 45–50 °C, add the powder, stirring constantly.
  • Simmer for 2 hours over minimal heat.
  • Cool, filter, and pour into a dark glass jar. The yield of the finished ointment is about 100 g.

Storage Conditions and Shelf Life (Ointment): Store in a cool, light-protected place, preferably in the refrigerator at a temperature of 4–8 °C. Avoid heating, exposure to moisture, and EMI. Shelf life — up to 3 months. After opening — use within 30 days.


Toxicity and Biosafety of Mucuna pruriens

The seeds of Mucuna pruriens are generally considered safe with oral administration in therapeutic dosages. At the same time, as with most biologically active plants, the safety of doses depends on the concentration of active substances, primarily L-Dopa.

Toxicological studies have shown that acute administration of Mucuna pruriens extract to animals demonstrates relatively low toxicity. According to a study conducted on rats, oral administration of the aqueous seed extract at a dose of up to 5000 mg/kg body weight did not cause lethal outcomes or pronounced clinical disorders, which indicates a high threshold of acute toxicity. Accordingly, the LD50 value with oral administration of the extract is more than 5000 mg/kg, which classifies it as a practically non-toxic substance (class V according to the WHO classification).

However, prolonged use of high doses or use in sensitive patients can lead to sleep disturbances, arterial hypertension, as well as exacerbation of psychoneurological conditions. In rare cases, gastrointestinal disorders are possible. When used in the form of unpurified raw seeds, skin and mucous membrane irritation is possible due to the content of trichomes that cause itching.

The study did not reveal hepatotoxic or nephrotoxic effects at standard dosages.

Reference: https://www.ncbi.nlm.nih.gov/p...


Pharmacodynamics — Mucuna pruriens

The pharmacodynamic action of Mucuna pruriens is determined primarily by the high content of the biogenic dopamine precursor — L-3,4-dihydroxyphenylalanine (L-Dopa), as well as the presence of alkaloids, flavonoids, lectins, and phytosteroids. The main mechanism of action is formed through the modulation of dopaminergic neurotransmission, which is manifested in the activation of dopamine D1 and D2 receptors at the level of the central nervous system. This causes a neuromodulatory and behavioral effect characteristic of dopaminergic agents. The bioavailability of natural L-Dopa from Mucuna pruriens extract has been confirmed in controlled studies, and in some cases its absorption efficiency is comparable to synthetic analogues.

Additionally, identified biologically active substances, including beta-sitosterol, gallic and ellagic acids, tannins, and levo-dopamine derivatives, possess pronounced antioxidant properties. They inhibit the formation of reactive oxygen species (ROS) and stabilize cell membranes, which reduces oxidative damage to neuronal tissues. These effects are especially pronounced at the systemic level with prolonged use of standardized forms. A high correlation has been noted between the L-Dopa content and a decrease in lipid peroxidation in the brain and liver of animal models.

Target systems of action include the nervous, endocrine, reproductive, and immune systems. At the level of the nervous system — the active substances of Mucuna participate in the regulation of the psychoemotional state through the activation of the mesolimbic and nigrostriatal dopaminergic system. At the endocrine level, a stimulating effect on the production of sex hormones in mammals has been recorded, which is associated with dopamine-dependent activation of the hypothalamic-pituitary axis.

Studies on cell cultures and animal models have shown that Mucuna pruriens seed extracts have an immunostimulating and adaptogenic effect, activating phagocytic activity and increasing the production of interleukins (in particular IL-2, IL-6) and γ-interferon. These properties suggest an influence on innate and adaptive immunity, especially under chronic stress influences. A modulating influence on cortisol levels, mediated through the CNS, has also been documented, which indicates a stress-protective effect of the plant.

Pharmacological targets of action include dopamine receptors (D1, D2), the aromatase enzyme, NADPH-dependent oxidase, as well as enzymes involved in testosterone synthesis and spermatogenesis. In vitro studies indicate the ability of Mucuna components to inhibit MAO-B, increasing the endogenous level of dopamine, and thereby enhancing dopaminergic transmission.

Separate attention is paid to the local action with external use: the alkaloid fractions of the plant have a weak analgesic and anti-inflammatory effect due to the inhibition of prostaglandin synthesis and the blocking of peripheral pain mediators. Bioflavonoids additionally provide an antihistamine and vascular-strengthening effect at the level of the skin and mucous membranes.

Thus, the pharmacodynamics of Mucuna pruriens combines central and peripheral mechanisms of action aimed at restoring neurotransmitter balance, antioxidant protection, immunomodulation, and endocrine regulation.

References:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669033
https://www.sciencedirect.com/science/article/abs/pii/S0378874102001207
https://www.tandfonline.com/do...
https://pubmed.ncbi.nlm.nih.gov/15182909
https://www.worldscientific.co...
https://www.semanticscholar.or...


Pharmacokinetics — Mucuna pruriens

The pharmacokinetic properties of Mucuna pruriens seeds have been studied predominantly with respect to dry extracts and powders used orally. The main active substances of the plant, including amino acid-like compounds, alkaloids, flavonoids, and saponins, demonstrate different pharmacokinetic profiles depending on the form and route of administration.

With oral intake, biologically active amino acid components possessing neurotropic activity are absorbed predominantly in the proximal part of the small intestine by means of active transport and passive diffusion. Assimilation depends on the state of the intestinal mucosa, the pH of the medium, and the presence of food components. The level of absorption is also influenced by competition with other amino acids consumed simultaneously with the preparation. Flavonoid and polyphenolic compounds present in the powder and tincture are partially metabolized by the intestinal microflora, forming more polar metabolites possessing antioxidant activity.

After absorption, the active components are distributed in the body with the participation of plasma proteins and easily penetrate the blood-brain barrier, influencing central neurotransmitter systems. Especially pronounced accumulation is observed in the tissues of the brain, liver, and reproductive organs. Some alkaloids and lipophilic fractions can accumulate in adipose tissue and be secondarily released upon mobilization of fat reserves.

Metabolism occurs predominantly in the liver with the participation of cytochrome P450 enzymes, as well as to an insignificant extent — in the kidneys and intestinal wall. Amino acid components undergo enzymatic decarboxylation and oxidation, resulting in the formation of physiologically active neurotransmitters and their metabolites. Flavonoids undergo phase II biotransformation with the formation of glucuronides and sulfates, which are easily excreted by the kidneys. The presence of saponins and other surface-active substances can increase the permeability of the intestinal wall and influence the pharmacokinetics of other compounds with combined use.

Excretion is carried out predominantly by the kidneys in the form of water-soluble metabolites, as well as to a lesser extent — with bile. Lipophilic and poorly metabolized components can be partially excreted through the skin and lungs. With transdermal and external use (ointment, oil infusion), absorption is limited to the surface layers of the skin; however, in some patients, systemic absorption is possible with prolonged use or application to extensive body areas. Mucous membranes (e.g., when using alcohol tinctures sublingually) provide faster and partial penetration of active substances into the bloodstream, bypassing the first pass through the liver.

The features of pharmacokinetics also depend on the state of the patient's hepato- and renal function, the state of the intestinal microflora, as well as on the form of administration: aqueous and alcohol extracts are absorbed faster than the whole powder but may have a shorter period of action. The powder and dry extract provide prolonged intake of active substances and contribute to their accumulation in target tissues.

References:
https://www.ncbi.nlm.nih.gov/p...
https://www.sciencedirect.com/...
https://pubmed.ncbi.nlm.nih.go...
https://link.springer.com/arti...
https://www.semanticscholar.or...


Mechanisms of Action and Scientific Rationale — Mucuna pruriens

The mechanisms of action of Mucuna pruriens are due to the combined effect of a group of bioactive compounds, including natural dopamine precursors, alkaloids, flavonoids, phenolic acids, lectin-like proteins, and triterpenoids. The most studied component is L-3,4-dihydroxyphenylalanine (L-Dopa), the main dopamine precursor, which acts as a central neurotransmitter modulator. After absorption in the intestine and penetration through the blood-brain barrier, L-Dopa is decarboxylated to dopamine, activating dopamine D1 and D2 receptors in the nigrostriatal and mesolimbic systems. This leads to stimulation of neuronal activity, enhancement of synaptic transmission, and neuroplasticity. There are data on the potentiation of the neurotrophic signaling cascade through participation in the activation of CREB and an increase in BDNF expression in brain tissues.

Polyphenolic fractions, especially flavonoids and ellagic acid derivatives, demonstrate antioxidant and anti-inflammatory properties through the suppression of the enzyme systems NADPH oxidase and lipoxygenase (LOX). These compounds inhibit the generation of reactive oxygen species (ROS) and reduce the activation of NF-κB cascades, which leads to a decrease in the expression of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. The ability of flavonoids to modulate the activity of cyclooxygenase-2 (COX-2), reducing the level of prostaglandins in tissues, has also been confirmed.

At the endocrine level, activation of the hypothalamic-pituitary-gonadal axis has been revealed, indirectly through dopamine-dependent inhibition of prolactin and possible stimulation of luteinizing hormone (LH), which may be mediated by the participation of the dopaminergic system in the regulation of gonadotropic function. Alkaloids and saponins isolated from Mucuna pruriens seeds are capable of interacting with androgen and glucocorticoid receptors, influencing steroid metabolism. Activity has been noted with respect to the modulation of steroidogenesis in Leydig cells.

The immunomodulatory effect is explained by an increase in the activity of macrophages and the production of interleukins (IL-2, IL-6, IFN-γ) through the activation of cellular signaling pathways JAK/STAT and PI3K/AKT. These effects are accompanied by enhanced proliferation of T cells and increased expression of surface molecules on antigen-presenting cells, including HLA-DR and CD86. It has also been established that the protein components of Mucuna can activate phagocytosis and neutrophil chemotaxis in vitro.

Neuroprotective properties are explained by the ability of the active components of the plant to reduce apoptosis of neuronal cells by suppressing caspase-3 expression and modulating the mitochondrial pathway (through the Bcl-2/Bax balance). The effects are mediated by activation of MAPK signaling pathways and inhibition of glutamate-induced excitotoxicity. Lipophilic triterpenoids and phytosterols additionally influence the integrity of neuronal membranes and reduce the level of oxidative lipid damage.

In animal studies, it has been established that Mucuna extracts are capable of inhibiting the activity of monoamine oxidase type B (MAO-B), which increases the level of dopamine in the synaptic cleft and reduces its catabolism. This confirms both the direct and indirect neurotransmitter effect of the plant.

References:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669033
https://www.sciencedirect.com/science/article/abs/pii/S0378874102001207
https://pubmed.ncbi.nlm.nih.gov/15182909
https://link.springer.com/article/10.1007/s10787-009-0030-z
https://www.semanticscholar.or...
https://www.tandfonline.com/do...


Synergy — Mucuna pruriens

The pharmacological synergy of Mucuna pruriens with other phytogenic and natural compounds has been confirmed in a number of in vitro, in vivo studies, and clinical observations. The most pronounced interaction is observed within the neuromodulatory, antioxidant, androgenic, and adaptogenic directions. The biological activity of Mucuna pruriens components can be potentiated through combination with other plants possessing similar mechanisms of action, especially in the field of regulation of dopaminergic transmission and protection of neuronal tissue.

The combination of Mucuna pruriens with adaptogens such as Withania somnifera and Panax ginseng demonstrates an additive and modulating effect on the endocrine and central nervous systems. Studies have shown that the combined use of extracts of these plants leads to an increase in the expression of neurotrophic factors (BDNF, NGF) and enhanced antioxidant activity at the level of brain cells. Simultaneous activation of dopamine receptors and a decrease in the expression of pro-inflammatory cytokines determine tissue-specific protection of neurons and potentiation of cognitive adaptation.

A potentiating effect has been established with combined use with flavonoid plants, for example Ginkgo biloba and Bacopa monnieri. Such interaction is realized due to the combined inhibition of MAO-B and enhancement of dopaminergic and cholinergic neurotransmission. Synergism is also observed in the stabilization of mitochondrial membranes and suppression of caspase-mediated apoptosis, which allows us to speak of systemic neuroprotection.

A synergistic interaction has been recorded when combining Mucuna pruriens with antioxidants of phenolic nature, including quercetin, ellagic acid, and resveratrol. This provides enhanced inhibition of oxidative stress through the suppression of NADPH oxidase activity and a decrease in the level of malondialdehyde (MDA). The effect is classified as potentiating, with a predominant action at the cellular level.

In the field of hormonal regulation, Mucuna pruriens interacts with phytosterol agents, including extracts of Tribulus terrestris and Eurycoma longifolia, providing an additive effect on the expression of LH receptors and an increase in endogenous testosterone. Combined use influences hypothalamic-pituitary regulation and can enhance the activity of Leydig cells through receptor-dependent mechanisms.

A modulating interaction with B vitamins and coenzymes (in particular, pyridoxine and niacin) involved in decarboxylation and catecholamine transformations has also been described, which may contribute to a more efficient conversion of biogenic amino acids into active mediators. This synergism is expressed in the stabilization of dopamine metabolism and an increase in the resistance of neurons to stress influences.

Finally, there is confirmation of a protective effect with the combined use of Mucuna pruriens with plants containing saponins, such as Glycyrrhiza glabra. These compounds can contribute to a decrease in the irritating effect of individual Mucuna alkaloids on the mucous membranes of the stomach and intestines, providing gastroprotection and improved bioavailability.

References:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669033
https://www.sciencedirect.com/science/article/abs/pii/S0378874102001207
https://pubmed.ncbi.nlm.nih.gov/15182909
https://link.springer.com/article/10.1007/s10787-009-0030-z
https://www.semanticscholar.or...
https://www.tandfonline.com/do...


Geography of Use and Traditional Medicine — Mucuna pruriens

Mucuna pruriens is a climbing liana widely distributed in the tropical and subtropical regions of Asia, Africa, and Latin America. Its ethnomedical significance has been recorded in various cultures of India, Sri Lanka, Thailand, Indonesia, Nigeria, Cameroon, Brazil, and a number of other South American countries. The most deeply rooted use is observed within the Indian Ayurvedic tradition, where the plant is known under the Sanskrit name "kapikacchu" and is considered a valuable tonic.

In Ayurveda, Mucuna seeds were traditionally used in the form of powder, infusions, and pastes, most often in combination with ghee, honey, or milk. A decoction of the roots was used less often — predominantly in dermatological practices. According to the treatises "Charaka Samhita" and "Bhava Prakasha," the plant belonged to the category of rasayana — remedies that strengthen vital force and reproductive energy. In the traditions of South Indian schools, the plant was also used as part of multicomponent formulas included in male strengthening regimens.

In African cultures, especially in West Africa, Mucuna seeds were used within the tribal phytotherapeutic practices of the Yoruba, Ewe, and Hausa peoples. Here, seed powder and aqueous infusion were used as a general tonic. In addition, in some regions of Ghana and Nigeria, roasted seeds were used as a coffee substitute or as a ritual component in initiation rites. There are known cases of including Mucuna in the composition of amulets and protective talismans worn by men during wedding ceremonies.

In the culture of the Maya and Quechua peoples of South America, especially in Bolivia and Peru, Mucuna is known as "frijol terciopelo" (velvet bean) and was traditionally used in the form of aqueous extracts or pastes applied to the body for the purpose of acquiring "inner strength." Some ethnographic reports mention the use of leaf juice or pod pulp in ritual rubbings during hunting or war rites. Cases of using the plant as a "guide plant" in the context of shamanic purification practices have also been described.

In Thailand, especially in the northern mountainous regions (Chiang Mai, Tak), representatives of the Karen and Lisu peoples use Mucuna as part of traditional preparations. The use is predominantly associated with male health, but decoctions of the roots are also mentioned in the practice of postpartum recovery in women. In the folk medicine of these communities, Mucuna powder is considered a "hot component" and is used in energetic tonic mixtures during the dry season.

According to archaeoethnobotanical data, the presence of Mucuna pruriens remains has been recorded in ceramics of the early Vedic period in the Ganges valley, which allows us to assume its use already around 1500 BC. It is also assumed that in ancient Chinese phytotherapy the plant was mentioned under the name "niu xi zi," but direct confirmation of this identification is insufficient.

In a ritual context, in addition to India and Africa, Mucuna was used by the peoples of Southeast Asia as a plant of purification. The seeds, containing small prickly trichomes, were used in rites of expelling "impure energy" through the induction of itching and burning — as a symbol of physical purification. In some Andamanese communities, the plant was part of smoking mixtures used in the context of inducing dreams or obtaining sleep after loss.

Thus, Mucuna pruriens possesses a centuries-long history of use in various regions of the world, both in medical and in ritual and ethnocultural contexts.

Specifications
Product type Extract, Powder
Weight 100 g
Made by Asiabiopharm Co Ltd
Country of origin Thailand
Reviews